Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD …

C Sobieski, E Gokdemir, W Wierda, N Jain, E Liu… - Leukemia, 2018 - nature.com
Ibrutinib, a covalent inhibitor of Bruton Tyrosine Kinase (BTK), is approved for treatment of
patients with relapsed/refractory or treatment-naïve chronic lymphocytic leukemia (CLL) …
被引用次数：129 相关文章

Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD …

K Kondo, H Shaim, PA Thompson… - …, 2018 - mdanderson.elsevierpure.com
Ibrutinib, a covalent inhibitor of Bruton Tyrosine Kinase (BTK), is approved for treatment of
patients with relapsed/refractory or treatment-naïve chronic lymphocytic leukemia (CLL) …
[PDF] researchgate.net

[PDF][PDF] Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD …

K Kondo, H Shaim, PA Thompson, JA Burger… - Leukemia, 2017 - researchgate.net
Chronic lymphocytic leukemia (CLL) is characterized by profound immunosuppression that
involves multiple T-cell defects. These include an exhausted T-cell phenotype marked by …
[HTML] nih.gov

[HTML][HTML] Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B cell function and inhibition of the PD …

K Kondo, H Shaim, PA Thompson, JA Burger… - Leukemia, 2018 - ncbi.nlm.nih.gov
Ibrutinib, a covalent inhibitor of Bruton Tyrosine Kinase (BTK), is approved for treatment of
patients with relapsed/refractory or treatment-naïve CLL. Besides directly inhibiting BTK …

Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD …

K Kondo, H Shaim, PA Thompson, JA Burger… - Leukemia, 2018 - go.gale.com
Chronic lymphocytic leukemia (CLL) is characterized by profound immunosuppression that
involves multiple T-cell defects. These include an exhausted T-cell phenotype marked by …

Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD …

K Kondo, H Shaim, PA Thompson, JA Burger… - …, 2018 - pubmed.ncbi.nlm.nih.gov
Ibrutinib, a covalent inhibitor of Bruton Tyrosine Kinase (BTK), is approved for treatment of
patients with relapsed/refractory or treatment-naïve chronic lymphocytic leukemia (CLL) …

Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD …

K Kondo, H Shaim, PA Thompson, JA Burger… - Leukemia, 2017 - europepmc.org
Ibrutinib, a covalent inhibitor of Bruton Tyrosine Kinase (BTK), is approved for treatment of
patients with relapsed/refractory or treatment-naïve CLL. Besides directly inhibiting BTK …

[引用][C] Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD …

K Kondo, H Shaim, PA Thompson, JA Burger… - Leukemia, 2017 - cir.nii.ac.jp
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated
suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway | CiNii …

Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD …

K Kondo, H Shaim, PA Thompson, JA Burger… - Leukemia, 2017 - europepmc.org
Ibrutinib, a covalent inhibitor of Bruton Tyrosine Kinase (BTK), is approved for treatment of
patients with relapsed/refractory or treatment-naïve CLL. Besides directly inhibiting BTK …